{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-089329","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.256226+00:00","generated_at":"2026-05-31T14:10:45.893030+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARCA biopharma Q2 net loss widens to $2.7M, cash $33.3M; merger with Oruka ongoing","bullets":["Net loss $2.7M ($0.18/sh) vs $1.5M ($0.10) in Q2 2023, driven by $1.3M increase in G&A expenses.","Cash $33.3M as of June 30, 2024, down from $37.4M at Dec 31, 2023; expects to fund ops through end of 2025.","G&A expenses rose to $3.0M from $1.7M due to $0.9M merger-related professional fees and $0.4M CEO termination benefits (Dr. Bristow resigned April 3, 2024).","Merger with Oruka Therapeutics remains pending; if not completed, company may pursue dissolution/liquidation.","R&D expenses fell to $0.1M from $0.3M due to reduced headcount and end of grants."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-089329","json":"https://secwatch.observer/filing/0000950170-24-089329.json","markdown":"https://secwatch.observer/filing/0000950170-24-089329.md","text":"https://secwatch.observer/filing/0000950170-24-089329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017024089329/0000950170-24-089329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017024089329/abio-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:10:45.893030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}